MétaCan
Menu
Back to cohort
Record W4220971556 · doi:10.1038/s41398-022-01847-8

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

2022· article· en· W4220971556 on OpenAlexafffundabout
Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, Julie‐Anne Tanner, Paige E. Davies, Paul Traxler, James Li, Elizabeth S. Cogan, Matthew Kucera, Ana Gugila, Nicole Braganza, Heather Emmerson, Gwyneth Zai, Daniel J. Müller, Robert D. Levitan, Stefan Kloiber, Zafiris J. Daskalakis, Benício N. Frey, James M. Bowen, Jean‐Éric Tarride, Richard Tytus, Ranjith Chandrasena, Nicholas C. Voudouris, Valerie H. Taylor, Raymond Tempier, Verinder Sharma, Akshya Vasudev, Peter Dzongowski, Lew Pliamm, Todd Greenspoon, Bryan Dechairo, James L. Kennedy

Bibliographic record

VenueTranslational Psychiatry · 2022
Typearticle
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsHamilton Health SciencesParkwood InstituteUniversity of OttawaThornhill Medical (Canada)University of CalgaryImpactTed Rogers Centre for Heart ResearchWestern UniversityUniversity of TorontoMontfort HospitalUniversity Health NetworkCentre for Addiction and Mental HealthPrograms for Assessment of Technology in Health Research InstituteSt. Joseph’s Healthcare HamiltonMcMaster University
FundersAssurex HealthOntario GenomicsGenome Canada
KeywordsRandomized controlled trialMajor depressive disorderMedicineDepression (economics)Hamilton Rating Scale for DepressionInternal medicineClinical trialPharmacogenomicsPhysical therapyPsychiatryPharmacology

Abstract

fetched live from OpenAlex

The pharmacological treatment of depression consists of stages of trial and error, with less than 40% of patients achieving remission during first medication trial. However, in a large, randomized-controlled trial (RCT) in the U.S. ("GUIDED"), significant improvements in response and remission rates were observed in patients who received treatment guided by combinatorial pharmacogenomic testing, compared to treatment-as-usual (TAU). Here we present results from the Canadian "GAPP-MDD" RCT. This 52-week, 3-arm, multi-center, participant- and rater-blinded RCT evaluated clinical outcomes among patients with depression whose treatment was guided by combinatorial pharmacogenomic testing compared to TAU. The primary outcome was symptom improvement (change in 17-item Hamilton Depression Rating Scale, HAM-D17) at week 8. Secondary outcomes included response (≥50% decrease in HAM-D17) and remission (HAM-D17 ≤ 7) at week 8. Numerically, patients in the guided-care arm had greater symptom improvement (27.6% versus 22.7%), response (30.3% versus 22.7%), and remission rates (15.7% versus 8.3%) compared to TAU, although these differences were not statistically significant. Given that the GAPP-MDD trial was ultimately underpowered to detect statistically significant differences in patient outcomes, it was assessed in parallel with the larger GUIDED RCT. We observed that relative improvements in response and remission rates were consistent between the GAPP-MDD (33.0% response, 89.0% remission) and GUIDED (31.0% response, 51.0% remission) trials. Together with GUIDED, the results from the GAPP-MDD trial indicate that combinatorial pharmacogenomic testing can be an effective tool to help guide depression treatment in the context of the Canadian healthcare setting (ClinicalTrials.gov NCT02466477).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.268
Threshold uncertainty score0.589

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.338
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations60
Published2022
Admission routes3
Has abstractyes

Explore more

Same venueTranslational PsychiatrySame topicTreatment of Major DepressionFrench-language works237,207